Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.35 |
| ▸ | MEN1 | O00255 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4746853 | 0.99 | CNR2 (0.36) | KMT2AMEN1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL4746051 | 0.96 | KMT2A (0.37) | KMT2AMEN1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL14080566 | 0.88 | KMT2A (0.41) | KMT2AMEN1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL14080613 | 0.88 | KMT2A (0.41) | KMT2AMEN1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL14080627 | 0.88 | KMT2A (0.41) | KMT2AMEN1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL14080720 | 0.87 | CNR2 (0.41) | KMT2AMEN1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL4746903 | 0.85 | KMT2A (0.42) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL4746052 | 0.84 | THRB (0.35) | KMT2AMEN1SMN1; SMN2LMNACNR2 | |
| SCHEMBL4788843 | 0.83 | ALDH1A1 (0.34) | KMT2AKDM4EALDH1A1NPSR1 | |
| SCHEMBL7509603 | 0.83 | CA1 (0.41) | KMT2ALMNAKDM4EALDH1A1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008112251-A1 | CYCLOPROPYL-CONTAINING POLYAMINE ANALOGS AS DISEASE THERAPIES | PROGEN PHARMACEUTICALS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20070232677-A1 | Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds | CELLGATE, INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007106554-A2 | TREATMENT AND PREVENTION OF VASCULAR HYPERPLASIA USING POLYAMINE AND POLYAMINE ANALOG COMPOUNDS | PROGEN PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232677-A1 | Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds | SRM, SMS, PCNA | KMT2A 562/4885MEN1 100/4885SMN1; SMN2 2501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.